Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year
Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially
Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter
Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range
Hosting conference call and webcast today at 8:30 a.m. ET
Xeris will host a conference call and webcast at 8:30 a.m. Eastern Time today to discuss the Company's financial and operational results. To pre-register for the conference call, please use the following link: https://www.netroadshow.com/events/login?show=ecd4fc1e&confId=76382
After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, March 20, 2025 at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 694296.
To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.